

no symptoms. Travellers, particularly pregnant women or their partners, should be counselled about possible risks and should be aware that we often do not have real-time regional epidemiological data on Zika virus transmission, and travel guidance should consider the limitations of available epidemiological data. Thailand, and presumably many countries in southeast Asia, have experienced variable transmission across many regions. The findings from Salje and colleagues regarding the distribution of symptomatic persons in Thailand heighten concerns there might be lower levels of population immunity than expected and therefore an ongoing risk to pregnant women travelling to or living in endemic settings.⁷

**Margaret A Honein, Martin S Cetron, Dana Meaney-Delman*
National Center on Birth Defects and Developmental Disabilities (MAH, DM-D), and National Center for Emerging and Zoonotic Infectious Diseases (MSC), Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
mhonein@cdc.gov

We declare no competing interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.

- 1 Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. *N Engl J Med* 2016; **374**: 1981–87.
- 2 WHO. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005). Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. 2016. [http://www.who.int/news-room/detail/01-02-2016-who-statement-on-the-first-meeting-of-the-international-health-regulations-\(2005\)-\(ihr-2005\)-emergency-committee-on-zika-virus-and-observed-increase-in-neurological-disorders-and-neonatal-malformations](http://www.who.int/news-room/detail/01-02-2016-who-statement-on-the-first-meeting-of-the-international-health-regulations-(2005)-(ihr-2005)-emergency-committee-on-zika-virus-and-observed-increase-in-neurological-disorders-and-neonatal-malformations) (accessed Nov 12, 2018).
- 3 Sassetti M, Ze-Ze L, Franco J, et al. First case of confirmed congenital Zika syndrome in continental Africa. *Trans R Soc Trop Med Hyg* 2018; **112**: 458–62.
- 4 Saxena SK, Kumar S, Sharma R, Maurya VK, Dandu HR, Bhatt ML. Zika virus disease in India—update October 2018. *Travel Med Infect Dis* 2018; published online Nov 3. DOI:10.1016/j.tmaid.2018.10.022.
- 5 Sasmono RT, Dhenni R, Yohan B, et al. Zika virus seropositivity in 1–4-year-old children, Indonesia, 2014. *Emerg Infect Dis* 2018; published online Sept 24. DOI:10.3201/eid2409.180582.
- 6 US Centers for Disease Control and Prevention. Zika travel information. 2018. <https://wwwnc.cdc.gov/travel/page/zika-travel-information> (accessed Nov 12, 2018).
- 7 Salje H, Tamrakar S, Lowe S, et al. Long-term circulation of Zika virus in Thailand: an observational study. *Lancet Infect Dis* 2018; published online Feb 27. [http://dx.doi.org/10.1016/S1473-3099\(18\)30718-7](http://dx.doi.org/10.1016/S1473-3099(18)30718-7).
- 8 Pacheco O, Beltran M, Nelson CA, et al. Zika virus disease in Colombia—preliminary report. *N Engl J Med* 2016; published online Jun 15. DOI:10.1056/NEJMoa1604037.
- 9 Rice ME, Galang RR, Roth NM, et al. Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection—U.S. territories and freely associated states, 2018. *MMWR Morb Mortal Wkly Rep* 2018; **67**: 858–67.
- 10 Hoen B, Schaub B, Funk AL, et al. Pregnancy outcomes after ZIKV infection in French territories in the Americas. *N Engl J Med* 2018; **378**: 985–94.
- 11 Orenstein WA, Bart KJ, Hinman AR, et al. The opportunity and obligation to eliminate rubella from the United States. *JAMA* 1984; **251**: 1988–94.

The STREAM trial: missed opportunities and lessons for future clinical trials



Final results of the STREAM trial were presented at the 2018, 49th Union World Conference on Lung Health, held in The Hague, The Netherlands. STREAM is a randomised controlled trial comparing the 18–24 month WHO-recommended multidrug-resistant tuberculosis (MDR-TB) treatment regimen with a 9–12 month regimen similar to that first described in Bangladesh.¹ Under programmatic conditions, the longer regimen results in treatment success for approximately 50% of patients,² whereas the shorter 9–12 month regimen improved treatment success to 80% or higher in selected countries.^{3,4} Because these countries had relatively low HIV prevalence and relatively high percentages of treatment success with the longer regimens, questions around generalisability were raised.⁴ STREAM was a multi-million dollar undertaking that took almost 10 years from the time of study design until the release of final results. Given the time and costs involved it is essential to reflect on lessons learned, and what the

trial results tell us to inform how we accumulate future evidence to guide MDR-TB treatment.

STREAM found that both the longer and shorter regimens performed well, with 80% and 79% favourable outcomes, respectively. In routine programmatic settings, loss to follow-up with the longer regimen is a major contributor to poor patient outcomes.² By contrast, previous studies of the shorter regimen documented reduced loss to follow-up, contributing to overall improved treatment success.^{3,4} However, because of the patient support provided in STREAM, as in most randomised controlled trials, the potential real-world effect of the shorter regimen on loss to follow-up could not be fully assessed. We must consider whether randomised controlled trials are the best way of evaluating the effect of a regimen on adherence and loss to follow-up. STREAM shows that improved patient support and encouragement during treatment improves

Published Online
March 22, 2019
[http://dx.doi.org/10.1016/S1473-3099\(19\)30106-9](http://dx.doi.org/10.1016/S1473-3099(19)30106-9)

treatment outcomes, irrespective of regimen composition and duration.

During the decade between STREAM's conception and final results, improved treatment outcomes with the shortened regimen in programmatic settings led to WHO recommending this regimen for MDR-TB treatment.⁵ Additionally, two new anti-tuberculosis drugs, bedaquiline and delamanid, also became available and because bedaquiline significantly improved MDR-TB patient outcomes, WHO prioritised its inclusion in all oral regimens in 2018.^{6,7} Randomised controlled trials have long been considered the gold standard in study design and probably contribute important data on regimen combinations, but given the extended time needed to plan and execute such trials, results might be programmatically irrelevant when finally available. Programmatic and large-scale operational research data^{3,7} have also contributed to a WHO recommendation for further operational studies of modified shorter regimens (including new drugs).⁶ Furthermore, newer and more innovative study designs need to be considered. Multi-arm, multi-stage trials allow for evaluation of more than one arm and flexibility to respond to new data,⁸ and Bayesian adaptive randomisation allows for reduced sample size and study time.⁹

STREAM's results also leave key questions unanswered, including the effectiveness of shortened treatment among HIV-positive patients, a group that was supposed to be a focus of the study. Overall, among HIV-positive patients, treatment success was lower and more serious adverse events and deaths occurred in the shorter than the longer treatment arm. Unfortunately, the study was insufficiently powered to definitively indicate which regimen reduces mortality and is better tolerated among this group. It is also disappointing that children were not included, because all the individual drugs in both arms are used routinely in children of all ages. Other outstanding questions include whether higher percentages of bacteriological failure documented in the shorter regimen signify a less bactericidal regimen, and whether the increased number of drug changes and loss to follow-up in the long regimen arm (contributing to poor treatment outcomes) simply reflect longer treatment duration.

Treatment adherence is a key issue in MDR-TB treatment. In-depth interviews with patients, to ascertain adherence challenges, would have contributed to a

better understanding of patient perspectives, fostering more patient-centred MDR-TB treatment. Additionally, permanent hearing loss—a frequent and debilitating adverse event in MDR-TB treatment—was not formally assessed. Only one of the four countries used audiology equipment to monitor hearing loss, with the remainder relying on whisper testing or self-report, thus missing a substantial proportion of mild or moderate hearing loss. Audiometry equipment is inexpensive, can be delivered using tablet technology,¹⁰ would have addressed the primary safety aims, while building effective MDR-TB treatment capacity in these low-income countries.

Although we have much to learn from the rigorous research of the STREAM trial, substantial work is needed to translate clinical trials into real-world conditions and extract the maximum cost-benefit. As *Mycobacterium tuberculosis* adapts and changes to its environment, we too need to adapt to the changing tuberculosis research environment to ensure attainment of the End TB strategy targets.

*Marian Loveday, Anja Reuter, Jennifer Furin, James A Seddon, Helen Cox

South African Medical Research Council, Durban, KwaZulu-Natal 4091, South Africa (ML); Centre for the AIDS Programme of Research in South Africa, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa (ML); Médecins Sans Frontières Khayelitsha, Cape Town, South Africa (AR); Harvard Medical School, Department of Global Health and Social Medicine, Boston, MA, USA (JF); Department of Paediatrics, Imperial College London, London, UK (JAS); Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa (JAS); and Division of Medical Microbiology and Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa (HC)
marian.loveday@mrc.ac.za

We declare no competing interests.

- 1 Nunn AJ, Rusen I, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. *Trials* 2014; **15**: 353.
- 2 Ahuja S, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. *PLoS Med* 2012; **9**: e1001300.
- 3 Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. *Am J Respir Crit Care Med* 2010; **182**: 684–92.
- 4 Aung K, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. *Int J Tuberc Lung Dis* 2014; **18**: 1180–87.
- 5 WHO. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
- 6 WHO. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization, 2018.

- 7 Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. *Lancet Respir Med* 2018; **6**: 699–706.
- 8 Phillips PPJ. Methodological considerations in clinical trials for new MDR-TB treatment regimens. *Int J Tuberc Lung Dis* 2016; **20**: 4–7.
- 9 Cellamare M, Milstein M, Ventz S, Baudin E, Trippa L, Mitnick C. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. *Int J Tuberc Lung Dis* 2016; **20**: 8–12.
- 10 Challenge TB. Audiometry in the management of drug-resistant tuberculosis version 1. 2017. https://www.challengetb.org/publications/tools/pmdt/Audiometry_in_the_Management_of_Drug_Resistant_TB.pdf (accessed Feb 17, 2018).

No accountability, no results—the difficult task of advocating for tuberculosis solutions



2017–18 saw two unprecedented events in the history of tuberculosis: the WHO Ministerial Conference, which was held in Moscow in November, 2017,¹ and the High-Level Meeting on tuberculosis at the UN General Assembly (UNGA) held in September, 2018.² The political declaration issued by UNGA pledged to achieve the targets envisaged by the End TB strategy³ through intermediate quantified milestones, focusing on vulnerable and marginalised populations, mobilising needed resources for research and implementation, and establishing a multisectoral accountability framework with regular reporting to UNGA. However, subsequent reflections have cast doubt over the effectiveness of the declaration, claiming that the outcomes did not include concrete political and financial commitments, especially by high-burden countries.^{4–6}

Is this surprising? Advocacy for this disease of voiceless people in extreme poverty has always been a challenge. It does not have a critical mass of champions capable of articulating compelling and hopeful messages worldwide. Communication has been focused on the negative aspects of the efforts to control the disease, in sharp contrast with that of HIV activists who have promoted positive messages, emphasising the progress made and the hopes for the future. As a result, the general perception about tuberculosis control efforts is often one of hopeless failure, despite the millions of lives saved since 1990, the over 5 million people cured every year, and the slow but steady decline in incidence and mortality. In addition, tuberculosis activism has often not been directed at those who can make meaningful changes. Acknowledging and publicising the major progress achieved could make tuberculosis investment a much more attractive proposition to politicians and decision makers focused on short-term goals.

Nonetheless, beyond advocacy and communication, there are deeply rooted challenges. As noted almost a decade ago,⁷ key UN agencies and their leaders have historically failed to prioritise tuberculosis as a major global health threat. Greater political commitment at WHO's highest level could have helped because when WHO is not bold, often ministers of health are not either. There have not been special initiatives by agencies, such as UNICEF, UNAIDS, or UNDP. With a couple of notable exceptions (eg, The United States Agency for International Development, US National Institutes of Health, and perhaps the Bill & Melinda Gates Foundation), important governmental and philanthropic funders are not committed to the fight against tuberculosis. There has not been a US presidential initiative on tuberculosis along the lines of what was done for HIV and malaria, nor have the European Commission and the G20 nations supported innovative solutions. The largest financing mechanisms, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and Unitaids, are still investing less than 20% of their funds in tuberculosis despite its promising progress. The World Bank has not paid tuberculosis special attention either, although three decades ago it promoted tuberculosis care as one of the most cost-effective health interventions.⁸ The private sector and pharmaceutical industry have little interest in tuberculosis. Discovery and marketing of new tools will almost certainly clash with their interests given tuberculosis geopolitics. In fact, the desired profits by a drug developer can hardly be achieved from sales in low-income and middle-income countries, which have more than 90% of the global tuberculosis burden. The fact that tuberculosis advocacy has been unable to promote positive, hopeful messages building on achievements is also reflected in the general sentiments about the UNGA

Published Online
March 22, 2019
[http://dx.doi.org/10.1016/S1473-3099\(19\)30105-7](http://dx.doi.org/10.1016/S1473-3099(19)30105-7)